YANTAI DONGCHENG PHARMACEUTICAL GROUP CO.,LTD. |
End-of-day quote
Other stock markets
|
5-day change | 1st Jan Change | ||
| 14.65 CNY | +2.81% |
|
+13.30% | -20.08% |
| May. 27 | Dongcheng Biochemicals' Unit Gets Nod to Trial Pancreatic Cancer Drug | MT |
| May. 07 | US FDA Grants Clinical Trial Approval for Dongcheng Biochemicals' Injection | MT |
| Sales 2024 * | 3.38B 467M | Sales 2025 * | 3.93B 542M | Capitalization | 12.08B 1.67B |
|---|---|---|---|---|---|
| Net income 2024 * | 301M 41.54M | Net income 2025 * | 462M 63.77M | EV / Sales 2024 * | 3.57 x |
| Net cash position 2024 * | - 0 | Net cash position 2025 * | - 0 | EV / Sales 2025 * | 3.07 x |
| P/E ratio 2024 * |
40.3
x | P/E ratio 2025 * |
26.1
x | Employees | 2,333 |
| Yield 2024 * |
1.02% | Yield 2025 * |
0.75% | Free-Float | 63.12% |
More Fundamentals
* Assessed data
More news
| 1 day | +2.81% | ||
| 1 week | +13.30% | ||
| 1 month | +5.93% | ||
| 3 months | -3.11% | ||
| 6 months | -17.51% | ||
| Current year | -20.08% |
1 week
13.31
15.11
1 month
12.6815.11
Current year
12.0519.08
1 year
12.0520.15
3 years
9.9422.98
5 years
9.9429.60
10 years
5.5029.60
| Managers | Title | Age | Since |
|---|---|---|---|
Zhi Gang Luo
CEO | Chief Executive Officer | 53 | 18-08-09 |
Qing Lin Liu
CHM | Chairman | 53 | 98-12-30 |
Chun Ping Zhu
DFI | Director of Finance/CFO | 59 | 98-12-30 |
| Members of the board | Title | Age | Since |
|---|---|---|---|
Shou Yi You
CHM | Chairman | 63 | 07-12-18 |
Xiao Jie Liu
BRD | Director/Board Member | 42 | 18-01-22 |
Chun Xiang Lue
PRN | Corporate Officer/Principal | 49 | 98-12-30 |
| Name | Weight | AuM | 1st Jan change | Investor Rating |
|---|---|---|---|---|
| 0.00% | 112 M€ | +4.61% | - |
| Date | Price | Change | Volume |
|---|---|---|---|
| 24-05-31 | 14.65 | +2.81% | 28,187,780 |
| 24-05-30 | 14.25 | +5.40% | 23,813,490 |
| 24-05-29 | 13.52 | +0.45% | 7,050,000 |
| 24-05-28 | 13.46 | -0.81% | 8,786,600 |
| 24-05-27 | 13.57 | +4.95% | 17,522,720 |
End-of-day quote Shenzhen S.E., May 30, 2024
More quotes
Yantai Dongcheng Biochemicals Co., Ltd is a China-based company principally engaged in the research, development, manufacture and sales of medical drugs. The Companyâs main products are categorized into active pharmaceutical ingredients (APIs), nuclear medicines, chemical drugs and traditional Chinese medicines, which include heparin sodium APIs, chondroitin sulfate, preparation products, radionuclide drugs and others. The Company distributes its products in domestic market and to overseas markets.
Sector
Pharmaceuticals
Calendar
2024-08-22
- Q2 2024 Earnings Release (Projected)
Trading Rating
Investor Rating
ESG Refinitiv
Sell
Buy
Mean consensus
BUY
Number of Analysts
7
Last Close Price
14.65
CNY
Average target price
19.9
CNY
Spread / Average Target
+35.84%
EPS Revisions
Annual profits - Rate of surprise
| 1st Jan change | Capi. | |
|---|---|---|
| -20.08% | 1.67B | |
| +16.08% | 41.97B | |
| +22.56% | 22.34B | |
| +16.04% | 15.25B | |
| +16.11% | 14B | |
| +49.88% | 12.06B | |
| -10.77% | 6.8B | |
| -0.05% | 6.79B | |
| -8.87% | 5.73B | |
| +14.18% | 5.49B |
- Stock Market
- Equities
- 002675 Stock
